Tenaya Therapeutics, Inc. files 10-Q

Here is a summary of the SEC periodic report for an investor: Tenaya Therapeutics reported a net loss of $19.3 million for the first quarter of 2026, a decrease from the $26.9 million net loss in the same period last year, primarily due to reduced operating expenses. The company ended the quarter with $80.9 million in cash and cash equivalents and believes this is sufficient to fund operations for at least the next twelve months.